Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673253 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL225434 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL1109091 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL6231982 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL160178 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL17283030 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL403933 | 0.94 | RAB9A (0.56) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL12837602 | 0.94 | RAB9A (0.56) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL1109093 | 0.91 | NPC1 (0.54) | GAATAS1R3TAS1R1LNPEPCA2 | |
| SCHEMBL12055633 | 0.91 | NPC1 (0.54) | GAATAS1R3TAS1R1LNPEPCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919887-B1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8263790-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7960573-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Children hospital medical center (US) | 2010-03-18 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1919887-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Girindus America, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | GAA 4613/4885KMT2A 3009/4885SLC1A2 2174/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | GAA 4613/4885KMT2A 3009/4885SLC1A2 2174/4885 |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | GAA 4613/4885KMT2A 3009/4885SLC1A2 2174/4885 |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | GAA 4613/4885KMT2A 3009/4885SLC1A2 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.